<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
0074-9011-99
</NDCCode>
<PackageDescription>
2.4 mL in 1 CARTRIDGE (0074-9011-99)
</PackageDescription>
<NDC11Code>
00074-9011-99
</NDC11Code>
<ProductNDC>
0074-9011
</ProductNDC>
<ProductTypeName>
DRUG FOR FURTHER PROCESSING
</ProductTypeName>
<ProprietaryName/>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Risankizumab
</NonProprietaryName>
<DosageFormName>
LIQUID
</DosageFormName>
<RouteName/>
<StartMarketingDate>
20250204
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
DRUG FOR FURTHER PROCESSING
</MarketingCategoryName>
<ApplicationNumber/>
<LabelerName>
AbbVie Inc.
</LabelerName>
<SubstanceName>
RISANKIZUMAB
</SubstanceName>
<StrengthNumber>
360
</StrengthNumber>
<StrengthUnit>
mg/2.4mL
</StrengthUnit>
<Pharm_Classes/>
<DEASchedule/>
<Status>
Unfinished
</Status>
<LastUpdate>
2025-03-04
</LastUpdate>
<PackageNdcExcludeFlag/>
<ProductNdcExcludeFlag/>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
04-FEB-25
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>